SIREN : 312815780
ALFAMED is a French company founded 48 years ago, specialized in the sector Fabrication de préparations pharmaceutiques. Based in CARROS (06510), this company of category ETI shows in 2024 a revenue of 12.6 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-09
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 12 571 429 € | 12 556 801 € | 14 479 444 € | 13 166 381 € | 12 897 669 € | 11 068 362 € | 11 391 893 € | 13 419 422 € | 14 617 869 € |
| Net income | 453 285 € | 506 041 € | 142 887 € | 273 193 € | 470 461 € | -3 554 930 € | 340 893 € | 610 769 € | 950 491 € |
| EBITDA | 522 491 € | 296 373 € | 350 300 € | 365 342 € | 421 034 € | -803 266 € | 651 131 € | 938 635 € | 1 263 536 € |
| Net margin | 3.6% | 4.0% | 1.0% | 2.1% | 3.6% | -32.1% | 3.0% | 4.6% | 6.5% |
In 2024, ALFAMED achieves revenue of 12.6 M€. Activity remains stable over the period (CAGR: -1.9%). Vs 2023: +0%. After deducting consumption (10.6 M€), gross margin stands at 2.0 M€, i.e. a rate of 16%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 522 k€, representing 4.2% of revenue. The operating margin remains fragile, requiring cost vigilance. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 453 k€, i.e. 3.6% of revenue. This profit can be retained or distributed to shareholders.
12 571 429 €
1 985 952 €
522 491 €
527 462 €
453 285 €
4.2%
The debt ratio (= Financial debt / Equity x 100) stands at 0%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 29%. The balance between equity and debt is satisfactory. Cash flow represents 2.8% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment.
0.007%
28.98%
2.823%
0.0
In 2024, the debt ratio of ALFAMED (0.01) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.
In 2024, the financial autonomy of ALFAMED (29.0%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
In 2024, the repayment capacity of ALFAMED (0.00) ranks in the bottom 25% of the sector, which is positive. This ratio indicates the number of years needed to repay debt with cash flow. A short capacity reflects controlled debt and good cash generation.
The liquidity ratio (= Current assets / Current liabilities) stands at 141.39. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 7.1x. Operating income very largely covers interest expenses: high safety margin.
141.394
7.12
In 2024, the liquidity ratio of ALFAMED (141.39) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.
In 2024, the interest coverage of ALFAMED (7.1x) ranks above the median of the sector. This ratio indicates how many times operating income covers interest expenses. This comfortable position offers an appreciable safety margin.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 37 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 64 days. Favorable situation: supplier credit is longer than customer credit by 27 days. Overall, WCR represents 90 days of revenue, i.e. 3.1 M€ to permanently finance. Over 2016-2024, WCR increased by +349%, requiring additional financing.
3 145 874 €
37 j
64 j
0 j
90 j
Indicative estimate only : the number of comparable transactions in this sector is limited (27 transactions). This range of 90 439€ to 277 974€ is provided for information purposes only and requires in-depth analysis to be confirmed.
This estimate is based on the analysis of 27 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare ALFAMED with other companies in the same sector:
Voir toutes les statistiques du secteur Fabrication de préparations pharmaceutiques
The revenue of ALFAMED in 2024 is 12.6 M€.
Yes, ALFAMED generated a net profit of 453 k€ in 2024.
The headquarters of ALFAMED is located in CARROS (06510), in the department Alpes-Maritimes.
The tax return of ALFAMED is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
ALFAMED operates in the sector Fabrication de préparations pharmaceutiques (NAF code 21.20Z). See the 'Sector positioning' section above to compare the company with its competitors.